Skip to main content
SpringerLink
Log in

Basic elements of applied pharmacology in the intensive care unit

  • Chapter
Critical Care Nephrology

  • 50 Accesses

Abstract

The care of critically ill patients often requires the use of many sophisticated techniques, including mechanical ventilation, invasive cardiac monitoring, continuous renal replacement, and a variety of pharmacotherapies. Virtually every patient admitted to the ICU will be treated with some drug, whether the patient is suffering from multi-organ failure or from a solitary lobar pneumonia. Throughout the hospital, there is no other location which presents such challenges to the physician, and proper dosing is important not only for treatment of the underlying disease process, but also to prevent drug toxicity in an unstable patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gibaldi M, Prescott L (eds). Handbook of Clinical Pharmacokinetics. Balgowlah, Australia: Adis Health Science Press, 1983.

    Google Scholar 

  2. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 4th Ed. New York: Lea & Febiger, 1991.

    Google Scholar 

  3. Gibaldi M, Perrier D. Pharmacokinetics. 2nd Ed. New York: Marcel Dekker, Inc. 1982.

    Google Scholar 

  4. Peck C. Bedside Clinical Pharmacokinetics. Rockville, Maryland: Pharmacometrics Press, 1985.

    Google Scholar 

  5. Flessner MF, Dedrick R. Intraperitoneal chemotherapy. The Textbook of Peritoneal Dialysis. Gokal R, Nolph KD (eds). Dordrecht: Kluwer Academic Publishers, 1994, 769–90.

    Book  Google Scholar 

  6. Hebbard GS, Sun WM, Bochner F, Horowitz M. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin Pharmacokinet 1995; 28: 41–66.

    Article  PubMed  CAS  Google Scholar 

  7. Wagner JG. Biopharmaceutics and Relavent Pharmacokinetics. Hamilton, Ill.: Drug Intelligence Publications, 1971, 215.

    Google Scholar 

  8. Berner B, John VA. Pharmacokinetic characteristics of transdermal delivery systems. Clin Pharmacokinet 1994; 26: 121–34.

    Article  PubMed  CAS  Google Scholar 

  9. Guy RH, Maibach HL. Drug delivery to local subcutaneous structures following topical administration. J Pharm Sci 1983; 72: 1375.

    Article  PubMed  CAS  Google Scholar 

  10. Schwartz ML. Antiarrhythmic effectiveness of intramuscular lidocaine: influence of different injection sites. Clin Pharmacol Ther 1974; 14: 77.

    CAS  Google Scholar 

  11. Bennett WM, Aronoff GR, Golper TA, Morrison G, Brater DC, Singer I. Drug Prescribing in Renal Failure. 3rd Ed. Philadelphia: American College of Physicians, 1994.

    Google Scholar 

  12. Chernow B. Critical Care Pharmacology. Baltimore: Williams and Wilkins, 1995.

    Google Scholar 

  13. Holford NHG. A standard size for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329–332.

    Article  PubMed  CAS  Google Scholar 

  14. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26: 292–307.

    Article  PubMed  CAS  Google Scholar 

  15. James WPT. Research on obesity. Her Majesty’s Stationary Office, London, 1976.

    Google Scholar 

  16. Devine BJ. Gentamicin therapy. Drug Intelligence and Clin Pharm 1974; 8: 650–5.

    Google Scholar 

  17. Gibaldi M, Levy G, McNamara PJ. Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther 1978; 24: 1–4.

    PubMed  CAS  Google Scholar 

  18. Routledge PA. The plasma protein binding of basic drugs. Eur J Clin Pharmac 1986; 22: 499–506.

    CAS  Google Scholar 

  19. Piafsky KM, Borga O. Plasma protein binding of basic drugs. II. Importance of a1-acid glycoprotein for inter-individual variation. Clin Pharmacol Ther 1977; 22: 545–9.

    PubMed  CAS  Google Scholar 

  20. Wallace SM, Riegelman S. Untake of acetazolamide by human erytrocytes in vitro. J Pharm Sci 1977; 66: 729–31.

    Article  PubMed  CAS  Google Scholar 

  21. Kurata D, Wilkinson GR. Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 16: 355–62.

    Google Scholar 

  22. Faed EM. Protein binding of drugs in plasma, interstitial fluid and tissues: effects on pharmacokinetics. Eur J Clin Pharmacol 1981; 21: 77–81.

    Article  PubMed  CAS  Google Scholar 

  23. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

    Article  Google Scholar 

  24. Rollins DE, Klaasen CD. Biliary excretion of drugs in man. Clin Pharmacokin 1979; 4: 368–79.

    Article  CAS  Google Scholar 

  25. Wiseman EH, Nelson E. Correlation of in vivo metabolism rate and physical properties of sulfonamides. J Am Pharm Assoc (Sci Ed) 1958; 47: 300.

    Google Scholar 

  26. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–60.

    Article  PubMed  CAS  Google Scholar 

  27. Bourget P, Roulot C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 1995; 28: 161–80.

    Article  PubMed  CAS  Google Scholar 

  28. Ward RM. Pharmacological treatment of the fetus. Clin Pharmacokinet 1995; 28: 343–50.

    Article  PubMed  CAS  Google Scholar 

  29. Crooks J, O’Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet 1976; 1: 280–96.

    Article  PubMed  CAS  Google Scholar 

  30. Hayton WL, Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 1986; 11: 76–86.

    Article  PubMed  CAS  Google Scholar 

  31. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 287–94.

    Article  PubMed  CAS  Google Scholar 

  32. Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis 1986; 8: 7–17.

    PubMed  CAS  Google Scholar 

  33. Terao N, Shen DD. Reduced extraction of 1-propranolol by perfused rat liver in the presence of uremic blood. J Pharm Exper Ther 1985; 233: 277–84.

    CAS  Google Scholar 

  34. Mac-Kay MV, Burson JS, Martinez-Lanao J, Dominguez-Gil A. Drug dosage in end-stage renal disease (ESRD): patients undergoing haemodialysis. Clin Pharmacokinet 1993; 25: 243–57.

    Article  PubMed  CAS  Google Scholar 

  35. Janknegt R, Nube MJ. A simple method for predicting drug clearances during CAPD. Perit Dial Bull 1985; 5: 254–5.

    Google Scholar 

  36. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24: 362–79.

    Article  PubMed  CAS  Google Scholar 

  37. Bressolle F, Kinowski J-M, Emmanuel de la Coussaye J, Wynn N, Eledjam J-J, Galtier M. Clinical pharmacokinetics during continuous haemofiltration. 1994; 26: 457–71.

    Article  CAS  Google Scholar 

  38. Paton TW, Cornish WR, Manuel MA, Hardy BG. Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 1985; 10: 404–26.

    Article  PubMed  CAS  Google Scholar 

  39. Hirszel P, Lameire N, Bogaert M. Pharmacologic alterations of peritoneal transport rates and pharmacokinetics of the peritoneum. The Textbook of Peritoneal Dialysis. Gokal R, Nolph KD (eds). Dordrecht: Kluwer Academic Publishers, 1994, 161–232.

    Google Scholar 

  40. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. In: Sieberth et al. (eds). Continuous hemofiltration. Contrib Nephrol 1991; 93: 110–6.

    Google Scholar 

  41. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin Pharmacokinet 1995; 29: 370–91.

    Article  PubMed  CAS  Google Scholar 

  42. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. Clin Pharmacokin 1988; 15: 94–113.

    Article  CAS  Google Scholar 

  43. Prescott LF, Adjepon-Yamoah KK, Talbot RG. Impaired lidocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J 1976; 1: 939–47.

    Article  PubMed  CAS  Google Scholar 

  44. Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995; 29: 15–28.

    Article  PubMed  CAS  Google Scholar 

  45. Gex-Fabry M, Balant LP. Considerations on data analysis using computer methods and currently available software for personal computers. chap 18 In: Welling PG, Balant LP (eds). Pharmacokinetics of Drugs. Berlin: Springer-Verlag, 1994, 507–27.

    Google Scholar 

Download references

Authors
  1. Michael F. Flessner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Flessner, M.F. (1998). Basic elements of applied pharmacology in the intensive care unit. In: Critical Care Nephrology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5482-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5482-6_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6306-7

  • Online ISBN: 978-94-011-5482-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation